WMSA
IMVT icon

Weiss Multi-Strategy Advisers’s Immunovant IMVT Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-75,631
Closed -$3.19M – 239
2023
Q4 		$3.19M Buy
75,631
+45,029
+147% +$1.66M 0.08% 309
2023
Q3 		$1.18M Sell
30,602
-102,174
-77% -$2.31M 0.03% 422
2023
Q2 		$2.52M Sell
132,776
-29,650
-18% -$553K 0.05% 432
2023
Q1 		$2.52M Buy
162,426
+92,420
+132% +$1.6M 0.06% 390
2022
Q4 		$1.24M Buy
+70,006
New +$881K 0.04% 439

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Weiss Multi-Strategy Advisers's IMVT Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 75,631 shares — an estimated $3.19M sold.

Weiss Multi-Strategy Advisers first reported a position in IMVT in Q4 2022 and held it in 5 quarters. The position peaked at $3.19M in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 75,631 Immunovant shares in Q1 2024, an estimated $3.19M.
  • Weiss Multi-Strategy Advisers first reported a position in Immunovant in Q4 2022 and held it in 5 quarters.
  • Weiss Multi-Strategy Advisers's Immunovant position peaked at $3.19M in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.